Evidence map›Paper›PMID 16143583›Full record

ArticleThorax2006

C-reactive protein in patients with COPD, control smokers and non-smokers.

V M Pinto-Plata, H Müllerova, J F Toso, M Feudjo-Tepie, J B Soriano, R S Vessey, B R Celli

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thorax, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02593357 (Assessment of a Peripheral Endothelial Dysfunction in COPD), which is not on this map. Cited by 155 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 6 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02593357 nacompletednot on this mapstarted 2012, after this paper: background citation

Assessment of a Peripheral Endothelial Dysfunction in COPD (Chronic Obstructive Pulmonary Disease)

TypeinterventionalSponsorHopital FochRan2012 to 2017Enrolled137ConditionsChronic Obstructive Pulmonary DiseaseArmsCOPD patients
3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 6 syntheses or guidelines pooled it, 438 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2017
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

V M Pinto-PlataPulmonary and Critical Care Division, Caritas St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA 02135, USA. vpinto@copdnet.org
H Müllerova
J F Toso
M Feudjo-Tepie
J B Soriano
R S Vessey
B R Celli
Tufts University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with chronic obstructive pulmonary disease (COPD) have raised serum levels of C reactive protein (CRP). This may be related directly to COPD and its associated systemic inflammation or secondary to other factors such as concomitant ischaemic heart disease (IHD) or smoking status. The aim of this study was to evaluate IHD and smoking as potential causes of raised CRP levels in COPD and to test the association between inhaled corticosteroid (ICS) use and serum CRP levels.

methodsCross sectional analyses comparing cohorts of 88 patients with COPD, 33 smokers (S), and 38 non-smoker (NS) controls were performed. Clinical assessments included a complete medical history, pulmonary function, 6 minute walk test (6MWT), cardiopulmonary exercise test, and high sensitivity serum CRP measurements.

resultsSerum CRP levels were significantly higher in patients with COPD (5.03 (1.51) mg/l) than in controls (adjusted odds ratio 9.51; 95% confidence interval 2.97 to 30.45) but were similar in the two control groups (S: 2.02 (1.04) mg/l; NS: 2.24 (1.04) mg/l). There was no clinical or exercise evidence of unstable IHD in any of the subjects. CRP levels were lower in COPD patients treated with ICS than in those not treated (3.7 (3.0) mg/l v 6.3 (3.6) mg/l); this association was confirmed in an adjusted regression model (p<0.05).

conclusionCRP levels are raised in COPD patients without clinically relevant IHD and independent of cigarette smoking, and reduced in patients with COPD using ICS. CRP may be a systemic marker of the inflammatory process that occurs in patients with COPD.

Indexed as

Adrenal Cortex HormonesCase-Control StudiesC-Reactive ProteinExercise TestExercise ToleranceFemaleForced Expiratory VolumeHumansMaleMyocardial IschemiaPulmonary Disease, Chronic ObstructiveSmokingVital CapacityAdrenal Cortex HormonesC-Reactive Protein

Identifiers

PMID16143583
PMCPMC2080714
OpenAlexW2191391362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.